Medpace Logo

For Immediate Release: October 25, 2018

Julie Hopkins
513-579-9911 x 12627

Medpace Expands Leadership for Hematology/Oncology Clinical Development

CINCINNATI, OH — (October 25, 2018) – Medpace (MEDP) a scientifically-driven, global, full-service clinical contract research organization (CRO) known for its strong therapeutic and regulatory expertise, announced the addition of three physicians to its growing team of hematology/oncology medical experts. Medpace’s unique, scientifically-driven approach to clinical research embeds medical expertise throughout trial design and execution, providing a high-science approach to clinical development.

“In response to the growing and dynamic market for innovative therapies such as CAR-T, immuno-oncology, and gene and cell therapies, Medpace continues to expand our team of in-house medical experts to support the needs around the globe,” explained Daniel O’Leary, Sr. Vice-President, Medical Department for Medpace. “Our mission is to accelerate the approval of safe and effective medical therapeutics and our reputation for taking on some of the industry’s most complex and innovative clinical trials demands that we continue to expand our depth of medical expertise. With the addition of these three highly-qualified physicians, Medpace can offer Sponsors even deeper expertise across a broad spectrum of diseases and technologies.”

Physicians Joining Medpace’s Hematology and Oncology Medical Department:

Cesar Casimiro, MD
Medical Director, Hematology & Oncology

Dr. Casimiro is a clinical oncologist bringing more than 20 years of professional medical experience in clinical trials to the Medpace team. He has extensive experience in managing the design, supervision, and development of global clinical trials across all phases for numerous drug indications. Dr. Casimiro provided medical oversight of clinical trials to ensure compliance with company Standard Operating Procedures, sponsor directives, and regulatory requirements. He also has a strong clinical background in cancer etiology, epidemiology and prevention, tumor biology, natural history, diagnosis and extension study, chemotherapy and hormone therapy use, supportive treatment and management of the terminal patient, and oncology emergencies treatment.

Dr. Casimiro received his medical degree from the Complutense University of Madrid in Madrid, Spain. He is a member of the Spanish Society on Medical Oncology and is extensively published in the peer-reviewed medical and scientific literature.

Jess N. Guarnaschelli, MD
Medical Director, Hematology & Oncology

Dr. Guarnaschelli is board-certified in radiation oncology and brings more than 15 years of experience in clinical research, academia, and clinical oncology practice. She is well versed in the design and conduct of clinical trials having worked with many devices and drug indications. Dr. Guarnaschelli has had extensive involvement in clinical trials of women’s oncologic diseases including breast, endometrial, cervical, and ovarian carcinoma. Her broader clinical oncology research and clinical background includes chemotherapeutics, immuno-oncology, and solid tumors.

Dr. Guarnaschelli received her bachelor’s degree from Brown University and her Doctor of Medicine from the University of Louisville School of Medicine in Louisville, KY. She completed her internship in General Surgery at Indiana University in Indianapolis, IN and completed her residency in Radiation Oncology at the University of Louisville School of Medicine. Dr. Guarnaschelli is an active member of numerous professional affiliations and societies including ASCO, SITC, and ASTRO. She is a peer reviewer for several medical journals and publications.

Agnes Slater, MBBS, PhD
Sr. Medical Director, Hematology & Oncology

Dr. Slater is a clinical research physician specialized in oncology and brings over 20 years of drug development experience in healthcare, academia and pharmaceutical industry. She provided medical monitoring and pharmacovigilance services for Phase I – IV global and Asia-Pacific regional studies. Dr. Slater has a substantial background in surgical oncology; biosimilars and innovative adaptive trial designs. She also contributed to product approval in oncology, metabolic disease and seizure disorders.

Dr. Slater received a Bachelor of Medicine and Bachelor of Surgery from Peking Medical University in Beijing, China. She received a Doctor of Philosophy in Pharmacology from the National University of Singapore and completed her Postdoctoral Clinical Fellowship at the Department of Surgery, National University Hospital, Singapore. She is an active member of ASCO and ESMO, and an associate member of Singapore Society of Oncology.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective.